RPHM Reneo Pharmaceuticals Inc

Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the Jefferies Biotech CNS/Neuro Summit.

Jefferies Biotech CNS/Neuro SummitDate: Wednesday, October 11, 2023 Location: Jefferies Conference Center, New York, NY

About Reneo PharmaceuticalsReneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Danielle Spangler Investor Relations Reneo Pharmaceuticals, Inc. dspangler@reneopharma.com

Matthew Purcell, Pharm.D.Media Inquiries Russo Partners, LLC matthew.purcell@russopartnersllc.com